CLAUDIN-6-PEPTIDE
European patent · EP3448879 · In force
Register entry
- Publication number
- EP3448879
- Application number
- EP17722139
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Apr 28, 2017
- Published
- Mar 6, 2019
- Granted
- Feb 26, 2025
- Protection ends at the latest
- Apr 27, 2037
- Next annual fee due
- Apr 30, 2027
- IPC classes
- C07K 14/47 (2006.01)A61K 38/00 (2006.01)A61P 35/00 (2006.01)G01N 33/574 (2006.01)G01N 33/68 (2006.01)C07K 14/725 (2006.01)C07K 14/74 (2006.01)
- Priority
- GB 201607534 29.04.2016
- PCT application
- PCT/GB2017/051193 28.04.2017
- PCT publication
- WO2017/187186 02.11.2017
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- May 1, 2026
Change
Published in Swissreg on 01.05.2026
- Jan 7, 2026
Change
Published in Swissreg on 07.01.2026
- May 1, 2025
Change
Published in Swissreg on 01.05.2025
- Mar 19, 2025
Owner
- Owner
- Immunocore Limited, 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, Adaptimmune Limited, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom → Immunocore Limited, 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom
Published in Swissreg on 19.03.2025
- Mar 19, 2025
Change
Published in Swissreg on 19.03.2025
- Feb 26, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 26.02.2025
Parties
Inventor
POWLESLAND, Alex
Abingdon Oxfordshire OX14 4RY, GB
SUN, Mei
Abingdon Oxfordshire OX14 4RY, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.